Guideline / position statementindependent cross-checkabstract checked I-INTB-11 standard review
International guideline for kidney-transplant care
KDIGO clinical practice guideline for the care of kidney transplant recipients.
Overview
KDIGO Transplant Work Group. Am J Transplant 2009 · PMID 19845597 · DOI 10.1111/j.1600-6143.2009.02834.x
Gives recommendations on immunosuppression and monitoring after kidney transplant.
Does the study support the specific claim? No · Methodological quality: moderate
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Guide transplant care
- How was the study done?
GRADE guideline
- How many people, animals or samples were studied?
not applicable
- What was actually found?
Recommendations on immunosuppression
- How large was the observed effect?
not applicable
- What do the results mean in everyday life?
Anti-rejection treatment and monitoring are standard after a kidney transplant.
- What are the study's limitations?
Abstract only
- What does it say about Elawady's specific claim?
Contradicts stopping all immunosuppression.
- Do the results apply to Germany and Europe?
High
Scientific in-depth review
1. Full reference
- Authors
- KDIGO Transplant Work Group
- Journal
- Am J Transplant
- Year
- 2009
- Identifier
- PMID 19845597 DOI 10.1111/j.1600-6143.2009.02834.x
- Verification
- verified – PubMed efetch 2026-10-25
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
no COI statement in record
2. Research question
How should kidney-transplant recipients be monitored and treated?
3. Study design and population
- Study design
- Guideline / position statement – International clinical practice guideline (GRADE-based)
- Population
Adults and children after kidney transplantation
- Country
International
- Period
2009
- Sample size
not applicable
- Inclusion and exclusion criteria
not applicable
4. Methods and endpoints
- Exposure / intervention
Immunosuppression, graft monitoring, infection, cardiovascular and malignancy prevention
- Comparator
not applicable
- Endpoints
Recommendations
- Statistical methods
GRADE
5. Actual results
- Results
Full guideline PDF (https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2009-Transplant-Recipient-Guideline-English.pdf, fetched 2026-10-26), chapter 3: Rec. 3.1 suggests the lowest planned maintenance doses by 2-4 months if no acute rejection (2C); Rec. 3.2 suggests that CNIs be continued rather than withdrawn (2B) and that prednisone used beyond the first week be continued rather than withdrawn (2C). Background: RCTs of complete CNI withdrawal (eight RCTs, 1891 patients) show some small benefit in graft function but significantly increased acute rejection without clear graft-survival benefit; RCTs show that steroid withdrawal more than 3 months after transplantation increases acute rejection. Chapter 7.2: for chronic allograft injury with histological CNI toxicity, reducing, withdrawing or replacing the CNI is suggested (2C).
- Absolute risks
not applicable
- Authors' conclusion
Evidence-based recommendations for immunosuppression and the prevention and treatment of complications in kidney-transplant recipients.
6. Strengths
- International, GRADE-based
7. Weaknesses
- Abstract only read; specific recommendation text not verified here
- 2009
8. Risk of bias
- Orienting tool
- none applicable
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- not assessable
- Rationale
Guideline.
Full-text review (26 October 2026): Chapter 3 recommendations and background read in the full guideline PDF; access remains abstract_only for the journal record because the whole document was not audited.
9. Assessment of the statistical interpretation
Guideline statements; supports that a short-term GFR gain after CNI withdrawal is expected and is accompanied by more rejection.
10. Relevance to the specific claim
Contradicts stopping immunosuppression outside medical supervision.
11. Independent contrary findings
12. Transferability to Germany and Europe
International, used in Europe.
13. Overall methodological judgement
Standard of care framework.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | moderate |
| Risk of bias | not assessable |
| Precision of results | not applicable |
| Directness | direct |
| Reproducibility | unknown |
| Consistency with the overall evidence | consistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |